{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:46Z","timestamp":1740120106665,"version":"3.37.3"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12185-022-03438-1","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T10:04:16Z","timestamp":1660730656000},"page":"856-862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison between filgrastim biosimilar and filgrastim original for the management of neutropenia after salvage chemotherapy for malignant lymphoma"],"prefix":"10.1007","volume":"116","author":[{"given":"Rena","family":"Shimano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1687-7029","authenticated-orcid":false,"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kashiwamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"3438_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/jjco\/hyt091","volume":"43","author":"Y Sagara","year":"2013","unstructured":"Sagara Y, Sato K, Fukuma E, Higaki K, Mizutani M, Osaki A, et al. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer. Jpn J Clin Oncol. 2013;43:865\u201373.","journal-title":"Jpn J Clin Oncol"},{"key":"3438_CR2","first-page":"867","volume":"51","author":"S Kiyama","year":"2015","unstructured":"Kiyama S, Kimura Y, Sakoda K, Nakamura M, Hamasaki S, Miura H, et al. Investigation of the effectiveness of an original filgrastim drug and a biosimilar. J Jpn Soc Hosp Pharm. 2015;51:867\u201370.","journal-title":"J Jpn Soc Hosp Pharm"},{"key":"3438_CR3","unstructured":"Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, et al. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic shock 2020 (J-SSCG2020). J Jpn Soc Intensive Care Med. 2021; 28."},{"key":"3438_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","volume":"18","author":"PS Becker","year":"2020","unstructured":"Becker PS, Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, et al. NCCN guidelines insights: hematopoietic growth factors, version 1.2020. J Natl Compr Canc Netw. 2020;18:12\u201322.","journal-title":"J Natl Compr Canc Netw"},{"key":"3438_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/bjh.14088","volume":"174","author":"K Kubo","year":"2016","unstructured":"Kubo K, Miyazaki Y, Murayama T, Shimazaki R, Usui N, Urabe A, et al. A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma. Br J Haematol. 2016;174:563\u201370.","journal-title":"Br J Haematol"},{"key":"3438_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1349-7006.2007.00662.x","volume":"99","author":"Y Oki","year":"2008","unstructured":"Oki Y, Ogura M, Kato H, Kikuchi A, Taji H, Kagami Y, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. Cancer Sci. 2008;99:179\u201384.","journal-title":"Cancer Sci"},{"key":"3438_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.5649\/jjphcs.41.793","volume":"41","author":"T Ohtsubo","year":"2015","unstructured":"Ohtsubo T, Nakagawa Y, Fujita M, Ishida Y, Sawada S, Tomogane K, et al. Comparison between filgrastim biosimilar \u201cMochida\u201d and filgrastim in malignant lymphoma: a prospective, randomized crossover comparative study. Jpn J Pharm Health Care Sci. 2015;41:793\u20138.","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"3438_CR8","unstructured":"https:\/\/www.mhlw.go.jp\/english\/. Accessed 16 Aug 2022."}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03438-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T21:38:32Z","timestamp":1700948312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03438-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03438-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}